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Abstract
A polymer-bound α, β-methylene-β-triphosphitylating reagent was synthesized and subjected to
reactions with unprotected nucleosides, followed by oxidation, deprotection of cyanoethoxy groups,
and acidic cleavage to afford nucleoside 5′-O-α, β-methylene-β-triphosphates. Among all the
compounds, cytidine 5′-O-α, β-methylene-β-triphosphate inhibited RNase H activity of HIV-1
reverse transcriptase with a Ki value of 225 μM.
Modified nucleoside triphosphates have received much attention as mimics of naturally
occurring deoxyribo- and ribonucleoside triphosphates, as probes in several biochemical
pathways involving DNA and RNA synthesis, and as potential diagnostic and therapeutic
agents.1,2 The structural similarity of modified nucleotides to natural nucleoside triphosphates
make them useful reagents as substrates or inhibitors for DNA or RNA polymerases.3,4
Although most natural polymerase enzymes incorporate natural nucleoside triphosphates into
nucleic acids, there are certain polymerases that are capable of incorporating unnatural
nucleoside triphosphates into nucleic acids.5–7
A number of approaches have been focused on modifications and/or substitution on the base,
8–9 carbohydrate,10–13 and linear triphosphate moieties14–17 to design modified nucleotides
for diverse applications in nucleic acid and antiviral research.
Early in the life cycle of human immunodeficiency virus type 1 (HIV-1), viral RNA is reverse
transcribed into double stranded DNA for integration into the genome of the infected cell.18
This process is catalyzed by reverse transcriptase (RT), a virus encoded heterodimeric enzyme
composed of 66 and 51 kD subunits (p66 and p51), possessing DNA polymerase and
ribonuclease H (RNase H) activities.19 DNA polymerase activity is required for the synthesis
of RNA: DNA heteroduplex from the single stranded viral RNA. Whereas, RNase H activity
†Electronic supplementary information (ESI) available: Experimental procedures, characterization of resins with IR and final compounds
with NMR, high-resolution mass spectrometry, and quantitative phosphorus analysis, DNA polymerase assay results.
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is responsible for hydrolyzing the RNA strand of RNA: DNA heteroduplex molecules that are
generated during reverse transcription and create the primer for plus strand DNA synthesis.
20 Both DNA polymerase and RNase H activities of HIV-1 RT have been considered as
potential targets for antiretroviral therapy. 3′-Substituted modified nucleoside triphosphate
analogues (e.g., 3′-azidodeoxythymidine triphosphate) are incorporated into DNA, behave as
chain terminators, and inhibit DNA synthesis by HIV-1 RT. On the other hand, the discovery
of potent and selective inhibitors of HIV-1 RNase H has been challenging, and inhibitors of
this enzyme function have yet to reach clinical development stage.18 Although there are more
than a dozen FDA approved drugs that inhibit the polymerase function of HIV-1 RT, there is
not a single RNase H inhibitor in clinics. Therefore, a potential RNase H inhibitor can serve
as a mechanistic probe and/or a lead compound against HIV-1 RT. Nucleotide analogues have
been described as inhibitors of HIV-1 RNase H activity.21,22
Less attention has been given to the synthesis of modified nucleotides containing branched
triphosphate groups that can have diverse applications in studying the enzymes (e.g., RNase
H) that use natural nucleoside triphosphates. Previously, we reported the synthesis of 5′-O-
nucleoside β-triphosphates using a solid-phase β-triphosphitylating reagent.23 Herein, we
report the solid-phase synthesis of 5′-O-nucleoside β-triphosphates containing α,β-methylene
triphosphate bridge by using a novel solid-phase phosphitylating reagent. The unusual
branched triphosphate in nucleoside triphosphate analogues may be useful in elucidation of
enzymatic functions and mechanism. Furthermore, the presence of an α, β-methylene group
in the modified nucleotide may provide more stability to cleavage by cellular hydrolytic
enzymes. We determined the potency of the modified analogues towards HIV-1 RT polymerase
and RNase H activity.
α,β-Methylene-β-triphosphitylating reagent was first immobilized on polystyrene resin-bound
linker of p-acetoxybenzyl alcohol. Coupling reactions of unprotected nucleosides with the
immobilized reagent followed by oxidation, deprotection, and cleavage afforded nucleoside
5′-O-α,β-methylene-β-triphosphates. The advantages of this solid-phase strategy included
major 5′-O-monophosphitylation, the facile isolation and purification of products, removal of
unreacted reagents and starting materials in each step, and trapping of the linker on the resin
in the final cleavage reaction.
Scheme 1 illustrates the synthesis of α,β-methylene β-triphosphitylating reagent 6. The reaction
of bis(dichloro-phosphino)methane (1) with diisopropylamine (1 equiv) in the presence of 2,6-
lutidine (1 equiv) in anhydrous THF afforded 2. Because of the bulkiness of the N,N-
diisopropylamine group, the replacement of −Cl groups in the less hindered phosphorous group
in 2 is significantly more desirable. Reaction of 2 with 3-hydroxypropionitrile (2 equiv) in the
presence of 2,6-lutidine (2 equiv) afforded 3, which was subjected to reaction with water (1
equiv) and 2,6-lutidine (1 equiv) to produce the intermediate 4.
In a separate reaction, phosphorus trichloride was reacted with 3-hydroxypropionitrile (1
equiv) in the presence of 2,6-lutidine (1 equiv) in anhydrous THF to yield 2-
cyanoethoxyphosphorodichloridite (5), which was reacted with 4 (1 equiv) to yield α,β-
methylene-β-triphosphitylating reagent 6, which was immediately used in the coupling reaction
with polymer-bound p-acetoxybenzyl alcohol 7. The chemical structure of 6 was confirmed
by high-resolution time-of-flight electrospray mass spectrometry (ESI-TOF), but obtaining
NMR for this compound was not feasible because of its rapid decomposition. Compound 6
was immediately used for the next coupling reaction with polymer-bound p-acetoxybenzyl
alcohol 7.
We have previously reported the synthesis of aminomethylpolystyrene resin-bound p-
acetoxybenzyl alcohol 7 (Scheme 2).24 Our earlier studies revealed the application of polymer-
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bound p-acetoxybenzyl alcohol linkers in the synthesis of a diverse number of compounds.25
Polymer-bound linker 7 was selected for immobilization of reagent 6.
Scheme 2 shows the synthesis of nucleoside 5′-O-α,β-methylene-β-triphosphates.
Aminomethyl polystyrene resin-bound linker of p-acetoxybenzyl alcohol 7 was reacted with
reagent 6 in the presence of 2,6-lutidine to produce the corresponding polymer-bound α,β-
methylene-β-triphosphitylating reagent (8). The treatment of excess of unprotected nucleosides
(adenosine (a), 3′-azido-3′-deoxythymidine (b), 3′-fluoro-3′-deoxythymidine (c), 2′,3′-
didehydrothymidine (d), cytidine (e), and inosine (f)) in the presence of 5-(ethylthio)-1H-
tetrazole gave 9a–f. Oxidation with t-butyl hydroperoxide followed by removal of the
cyanoethoxy group with DBU, afforded the corresponding polymer-bound nucleosides 5′-O-
α,β-methylene-β-triphosphosphate diester derivatives, 11a–f. The cleavage of polymer-bound
compounds was carried out under acidic conditions, DCM/TFA/water/EDT (72.5: 23: 2.5: 2
v/v/v/v). The intramolecular cleavage mechanism of final products from 12a–f is shown in
Scheme 2. The linker-trapped resin (13) was separated from the final products by filtration and
was converted to 14 by reaction with potassium hydroxide. The crude products had a purity of
68–83% and were purified on the C18 Sep-Pak cartridges to afford 5′-O-nucleoside α,β-
methylene-β-triphosphates (15a–f, Scheme 2) in 47–73% overall yield (calculated from 8,
212–344 mg, Table S1, see the Supporting Information†).
Nucleoside 5′-O-α,β-methylene-β-triphosphates were synthesized with high selectivity as a
result of this sequence because of the presence of the phosphitylating reagent on the solid
support having a hindered structure, thereby allowing for the regioselective reaction for
unprotected nucleosides (e.g., adenosine, inosine, and cytidine). The most reactive hydroxyl
group of unprotected nucleosides reacted selectively with hindered polymer-bound reagents
when an excess of nucleoside was used. There was no need to protect the free amino group in
adenosine and cytidine. The compounds were characterized by 1H NMR, 13C NMR, 31P NMR,
ESI-TOF, and phosphorus elemental analysis. 31P NMR indicated the presence of only one
diastereoisomer, suggesting that one of the diastereoisomers of each compound was purified
from the crude as the major product. On the other hand, there is a slight possibility that
diastereoisomers may not be distinguishable by 31P NMR because of overlapping peaks.
Purification of HIV-1 RT and enzyme assays was performed according to the previously
reported procedures.26–28 Initially, these compounds were screened towards the polymerase
and RNase H activity of HIV-1 RT at a fixed concentration of the compound (1 mM). In
comparison to the wild type enzyme, the polymerase activity was not affected in the presence
of these compounds 15a–f, however a few compounds exhibited inhibitory activity against
RNase H function. The results of the polymerase assay are presented in Figure S1 (see
Supporting Information†).
The results of the RNase H analysis are presented in Fig. 1A. Lane W represents the RNase H
cleavage products representative of the primary and secondary cleavages in the absence of any
inhibitor. Lanes a–f represent the RNase H cleavage products in the presence of the compounds
15a–f, respectively. Although compounds 15a–d and 15f did not show any inhibitory activity,
the RNase H cleavage of HIV-1 RT was inhibited by 5′-O-cytidine α,β-methylene-β-
triphosphate (15e) (Fig. 1A, Lane e). To further evaluate the inhibitory potency of 15e, RNase
H assay was performed at increasing concentrations of 15e. Since RNase H inhibition was not
observed up to 100 μM concentration, the results from 100 μM–1mM are presented in Fig. 1B.
†Electronic supplementary information (ESI) available: Experimental procedures, characterization of resins with IR and final compounds
with NMR, high-resolution mass spectrometry, and quantitative phosphorus analysis, DNA polymerase assay results.
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To further characterize the nature of inhibition, we performed Dixon analysis for the compound
15e.29a The results of this analysis indicated a competitive mode of inhibition with a Ki value
of 225 μM (Fig. 2). Subsequently, the IC50 value was calculated to be 585 μM for compound
15e by the Cheng–Prusoff equation29b for competitive inhibition [i.e., K i = IC50/(1+ [S]/
Km)] towards the RNase H activity of HIV-1 RT.
To the best of our knowledge, this is the first report of the synthesis of nucleoside 5′-O-α,β-
methylene-β-triphosphates. This solid-phase methodology using novel polymer-bound
phosphitylating reagent (8) allowed for the expeditious development of these analogues in a
short synthetic route without the need for the nucleoside phosphate precursors or protected
nucleosides. The solid-phase strategy offered the advantages of monosubstitution, high
selectivity, and facile isolation and purification of products. Further exploring and optimization
of 5′-O-cytidine α,β-methylene-β-triphosphate is required to design cell-permeable compounds
that can potentially inhibit the RNase H activity of HIV-1 RT at lower concentrations.
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Fig. 1.
A. RNase H analysis of HIV-1 RT in the presence of compounds 15a–e. Lane w represents no
inhibitor, lane a (15a), lane b (15b), lane c (15c), lane d (15d), lane e (15e), and lane f (15f),
at 1 mM concentrations. B. RNase H activity as a function of compound 15e concentration.
Lane 1 (100 μM), lane 2 (200 μM), lane 3 (300 μM), lane 4 (400 μM), lane 5 (500 μM), lane
6 (700 μM), and lane 7 (1 mM). The unhydrolyzed substrate is marked as U, whereas the
cleavage products are marked as C. The RNase H cleavage of HIV-1 RT was inhibited by 5′-
O-cytidine α,β-methylene-β-triphosphate (15e).
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Fig. 2.
Inhibition kinetics analyses of compound 15e with RNase H of HIV-1 RT. The enzyme activity
was estimated using the substrate at 200 nM (▲) and 400 nM (■) at increasing concentrations
of 15e. Rate of reaction represents rate of RNase H hydrolysis. Reciprocals of the rate of
hydrolysis were plotted versus the inhibitor concentrations. The straight lines indicated the best
fit of the data obtained. The inhibition constant Ki was calculated from the point of the
intersection of the plots.
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Scheme 1.
Synthesis of α,β-methylene-β-triphosphitylating reagent 6.
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Scheme 2.
Synthesis of nucleoside 5′-O-α,β-methylene-β-triphosphates 15a–f using polymer-bound
linker 7.
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